Benabdallah N, Williamson I, Illingworth R, Kane L, Boyle S, Sengupta D, et al. Decreased Enhancer-Promoter Proximity Accompanying Enhancer Activation. Mol Cell. 2019;76:473-484.e7 pubmed publisher

Mengwasser K, Adeyemi R, Leng Y, Choi M, Clairmont C, D Andrea A, et al. Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets. Mol Cell. 2019;73:885-899.e6 pubmed publisher

Okamoto K, Ohishi T, Kuroiwa M, Iemura S, Natsume T, Seimiya H. MERIT40-dependent recruitment of tankyrase to damaged DNA and its implication for cell sensitivity to DNA-damaging anticancer drugs. Oncotarget. 2018;9:35844-35855 pubmed publisher

Singh R, van Haandel L, Heruth D, Ye S, Leeder J, Becker M, et al. Nicotinamide Phosphoribosyltransferase Deficiency Potentiates the Antiproliferative Activity of Methotrexate through Enhanced Depletion of Intracellular ATP. J Pharmacol Exp Ther. 2018;365:96-106 pubmed publisher

Vanden Heuvel J, Bullenkamp J. Registered report: Systematic identification of genomic markers of drug sensitivity in cancer cells. elife. 2016;5: pubmed publisher

Du Y, Yamaguchi H, Wei Y, Hsu J, Wang H, Hsu Y, et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med. 2016;22:194-201 pubmed publisher

Howard S, Yanez D, Stark J. DNA damage response factors from diverse pathways, including DNA crosslink repair, mediate alternative end joining. PLoS Genet. 2015;11:e1004943 pubmed publisher

Hill S, Clark A, Silver D, Livingston D. BRCA1 pathway function in basal-like breast cancer cells. Mol Cell Biol. 2014;34:3828-42 pubmed publisher

Heitmann J, Geeleher P, Zuo Z, Weichselbaum R, Vokes E, Fetscher S, et al. Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer. Oral Oncol. 2014;50:825-31 pubmed publisher

Jelinic P, Levine D. New insights into PARP inhibitors' effect on cell cycle and homology-directed DNA damage repair. Mol Cancer Ther. 2014;13:1645-54 pubmed publisher

McMullin R, Wittner B, Yang C, Denton Schneider B, Hicks D, Singavarapu R, et al. A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity. Breast Cancer Res. 2014;16:R25 pubmed publisher